Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis

doi:10.3748/wjg.v30.i34.3929

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (724)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

555

Sum=574

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=98

Sep 14, 2024 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Sep 14, 2024; 30(34): 3929-3931
Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3929

Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis

Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás

Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal

Author contributions: Lopes SR and Martins C analyzed the data and wrote the manuscript; All authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Claudio Martins, MD, Doctor, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Rua Camilo Castelo Branco, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt

Received: April 14, 2024
Revised: August 10, 2024
Accepted: August 23, 2024
Published online: September 14, 2024
Processing time: 148 Days and 21.2 Hours

Core Tip

Core Tip: Tofacitinib, an oral small-molecule agent, has proven efficacy in inducing and maintaining remission among patients with moderate-to-severe ulcerative colitis. Real-world studies have showcased its effectiveness and safety profile to treat ulcerative colitis, primarily within Western countries. There have been a limited number of studies conducted on Asian patients.